Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions

Current Opinion in Biotechnology

Volumn 10, Issue 6, 1999, Pages 564-570

  Michalik, Liliane ^a   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; FATTY ACID; ICOSANOID; ISOPROTEIN; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ATHEROSCLEROSIS; BINDING SITE; FATTY ACID METABOLISM; GENE EXPRESSION REGULATION; GENE TARGETING; ICOSANOID METABOLISM; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032710343     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(99)00030-0     Document Type: Review

References (54)

1. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPARalpha, beta and gamma in the adult rat. Endocrinology. 137:1996;354-366.
2. Shalev A., Siegrist-Kaiser C.A., Yen P.M., Wahli W., Burger A.G., Chin W.W., Meier C.A. The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin. Endocrinology. 137:1996;4499-4502.
3. Juge-Aubry C.E., Hammar E., Siegrist-Kaiser C., Pernin A., Takeshita A., Chin W.W., Burger A.G., Meier C.A. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem. 274:1999;10505-10510. PPARs are subject to phosphorylation by insulin, resulting in the activation of PPARα and inhibition of PPARγ under certain conditions. Analysis of the amino-terminal region of PPARα revealed that the insulin-induced transactivation occurs through the phosphorylation of two mitogen-activated protein kinase sites at positions 12 and 21, both of which must be phosphorylated in order to activate transcription. Interestingly, the stimulatory effect of phosphorylation can be mimicked by the addition of tri-iodothyronine receptor β1, a strong binder of co-repressor proteins but not by a mutant deficient in interacting with co-repressors. These observations suggest that the AF-1 region of PPARα is partially silenced by co-repressor proteins that might be released upon phosphorylation of the above-mentioned sites.
4. Zhang B., Berger J., Zhou G., Elbrecht A., Biswas S., White-Carrington S., Szalkowski D., Moller D.E. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 271:1996;31771-31774.
5. Camp H.S., Tafuri S.R. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem. 272:1997;10811-10816.
6. Adams M., Reginato M.J., Shao D., Lazar M.A., Chatterjee V.K. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem. 272:1997;5128-5132.
7. Hu E., Kim J.B., Sarraf P., Spiegelman B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR gamma. Science. 274:1996;2100-2103.
8. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 11:1997;779-791.
9. Onate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 270:1995;1354-1357.
10. Dowell P., Ishmael J.E., Avram D., Peterson V.J., Nevrivy D.J., Leid M. p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha. J Biol Chem. 272:1997;33435-33443.
11. DiRenzo J., Soderstrom M., Kurokawa R., Ogliastro M.H., Ricote M., Ingrey S., Horlein A., Rosenfeld M.G., Glass C.K. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol. 17:1997;2166-2176.
12. Zamir I., Zhang J., Lazar M. Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev. 11:1997;835-846.
13. Dowell P., Ishmael J.E., Avram D., Peterson V.J., Nevrivy D.J., Leid M. Identification of nuclear receptor corepressor as a peroxisome proliferator-receptor alpha interacting protein. J Biol Chem. 274:1999;15901-15907. Nuclear receptor co-repressor (NCoR) can interact strongly with PPARα, and suppress PPARα-dependent transcriptional activation. This repression in mammalian cells was reversed by agonists of either PPARα or its heterodimeric partner RXRα. Thus, NCoR appears to influence PPARα signaling pathways and, therefore, might modulate tissue responsiveness of the PPAR-RXR heterodimer.
14. Jpenberg I., Jeannin A., Wahli E., Desvergne W., Polarity B. and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor (RXR) heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem. 272:1997;20108-20117.
15. Kersten S., Wahli W. Adopting orphans: finding ligands. Picard D. Nuclear Receptors. A Practical Approach. 1999;71-93 Oxford University Press, Oxford, UK.
16. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., Sternbach D.D., Lehmann J.M., Wisely G.B., Willson T.M.et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 3:1999;397-403. The authors describe the crystal structure of the PPARβ ligand-binding domain bound either to eicosapentaenoic acid (EPA) or a synthetic fibrate.The structures reported provide insights into the propensity of PPARs to interact with a variety of synthetic and natural compounds, including fatty acids that vary both in chain length and degree of saturation.
17. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Millburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 395:1998;137-143. The crystal structure of the human apo-PPARγ ligand-binding domain (LBD) is presented. This structure reveals a large binding pocket, which may explain the diversity of ligands for PPARγ. The structure of a ternary complex containing the PPARγ LBD, the antidiabetic ligand rosiglitazone (BRL49653), and 88 amino acids of human SRC-1 was also solved. The results obtained, together with the observation that two consecutive LXXLL motifs of SRC-1 make identical contacts with both subunits of a PPARγ homodimer, suggest a general mechanism for the assembly of nuclear receptors with co-activators.
18. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 272:1997;3406-3410.
19. Berger J., Leibowitz M.D., Doebber T.W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C.A., Hayes N.S., Li Y.et al. Novel peroxisome proliferator-activated receptor gamma and delta ligands produce distinct biological effects. J Biol Chem. 274:1999;6718-6725.
20. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 68:1992;879-887.
21. Zhang B., Marcus S.L., Sajjadi F.G., Alvares K., Reddy J.K., Subramani S., Rachubinski R.A., Capone J.P. Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci USA. 89:1992;7541-7545.
22. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 15:1995;3012-3022.
23. Schoonjans K., Watanabe M., Suzuki H., Mahfoudi A., Krey G., Wahli W., Grimaldi P., Staels B., Yamamoto T., Auwerx J. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem. 270:1995;19269-19276.
24. Motojima K., Passilly P., Peters J.M., Gonzalez F.J. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem. 273:1998;16710-16714. An obligatory role of PPARα in hepatic fatty acid translocase (FAT) and fatty acid transport protein (FATP) induction was demonstrated. In white adipose tissue of KKAy obese mice, PPARγ activators (pioglitazone and troglitazone) induced FAT and FATP more efficiently than the PPARα activator clofibrate. This effect was absent in brown adipose tissue. These results demonstrate that tissue-specific expression of FAT and FATP genes involves both PPARα and γ. Furthermore, it shows that PPAR ligands not only influence the metabolism of intracellular fatty acids but also their cellular uptake, which most probably represents an important regulatory step in lipid homeostasis.
25. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev. 20:1999;649-688.
26. Mascaro C., Acosta E., Ortiz J.A., Marrero P.F., Hegardt F.G., Haro D. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem. 273:1998;8560-8563.
27. Brandt J.M., Djouadi F., Kelly D.P. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem. 273:1998;23786-23792.
28. Rodriguez J.C., Gil-Gomez G., Hegardt F.G., Haro D. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem. 269:1994;18767-18772.
29. Muerhoff A.S., Griffin K.J., Johnson E.F. The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. J Biol Chem. 267:1992;19051-19053.
30. Aldridge T.C., Tugwood J.D., Green S. Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J. 306:1995;473-479.
31. Tontonoz P., Hu E., Devine J., Beale E.G., Spiegelman B.M. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol. 15:1995;351-357.
32. Ribon V., Johnson J.H., Camp H.S., Saltiel A.R. Thiazolidinediones and insulin resistance: peroxisome proliferator activated receptor gamma activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA. 95:1998;14751-14756. The restricted expression of c-Cbl-associated protein (CAP), a signaling protein that interacts with the insulin receptor, in cells metabolically sensitive to insulin suggests an important potential role in insulin action. The expression of CAP mRNA and proteins is increased through transcriptional stimulation by PPARγ ligands in 3T3-L1 adipocytes. Administration of the thiazolidinedione troglitazone to Zucker (fa/fa) rats also increased the expression of the protein in adipose tissue. Thus, the CAP gene appears to be sensitive to PPARγ and may play a role in thiazolidinedione-induced insulin sensitization.
33. Djouadi F., Weinheimer C.J., Saffitz J.E., Pitchford C., Bastin J., Gonzalez F.J., Kelly D.P. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. Clin Invest. 102:1998;1083-1091. The expression of PPARα target genes was characterized in response to a perturbation in cellular lipid oxidative flux caused by pharmacological inhibition of mitochondrial fatty acid import. This inhibition caused a feedback stimulation of PPARα target genes encoding fatty acid oxidation enzymes in liver and heart. In PPARα null mice, this inhibition caused massive hepatic and cardiac lipid accumulation, hypoglycemia, and death in 100% of male but only in 25% of female null-mice. Pretreatment of the males with β-estradiol rescued the metabolic phenotype. Thus, both PPARα and estrogen signaling pathways play a pivotal role in the regulation of cardiac and hepatic lipid metabolism.
34. Lemberger T., Saladin R., Vazquez M., Assimacopoulos F., Staels B., Desvergne B., Wahli W., Auwerx J. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem. 271:1996;1764-1769.
35. Kersten S., Seydoux J., Peters J.M., Gonzalez F.J., Desvergne B., Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptative response to fasting. J Clin Invest. 103:1999;1489-1498. Release of large amounts of fatty acids from the adipose tissue, followed by their oxidation in the liver, is induced by deprivation of food. As the nuclear receptor PPARα plays a role in regulating mitochondrial and peroxisomal fatty acid oxidation, it is likely to be involved in the transcriptional response to fasting. To test this possibility, PPARα null-mice were subjected to fasting and their response compared to wild-type mice. Fasted PPARα null-mice showed a massive accumulation of lipid in the liver and displayed severe hypoglycemia, hypoketonemia and hypothermia, which suggests a dramatic impairment of fatty acid oxidation.
36. ••] are reported. The phenotype of fasted PPARα null mice resembles that of humans with genetic defects in mitochondrial fatty acid oxidation enzymes and identifies PPARα null mice as a potentially useful mouse model of inborn or acquired defects of fatty acid utilization in human.
37. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARalpha leukotriene B4 pathway to inflammation control. Nature. 384:1996;39-43.
38. von Schacky C., Kiefl R., Marcus A.J., Broekman M.J., Kaminski W.E. Dietary n-3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes. Biochim Biophys Acta. 1166:1993;20-24.
39. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C.et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 393:1998;790-793. The authors show that PPARα is expressed in human aortic smooth-muscle cells. In these cells, they find that PPARα ligands inhibit IL-1-induced production of IL-6 and prostaglandin, as well as the expression of cyclooxygenase-2. This inhibition results from a PPARα repression of NF-κB signaling. In hyperlipidaemic patients, fenofibrate treatment decreases the plasma concentrations of IL-6, fibrinogen and C-reactive protein. The authors conclude that activators of PPARα inhibit the inflammatory response of aortic smooth-muscle cells and decrease the concentration of plasma acute-phase proteins. This suggests that PPARα in the vascular wall may influence the process of atherosclerosis and re-stenosis.
40. Poynter M.E., Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 273:1998;32833-32841.
41. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation. Nature. 391:1998;79-82. In response to 15d-PGJ2 and synthetic PPARγ ligands, PPARγ is markedly upregulated in activated peritoneal macrophages and the expression of the inducible nitric oxide synthase, gelatinase B and scavenger receptor A genes is inhibited. These effects are mediated in part by antagonizing the activities of the transcription factors AP-1, STAT and NF-κB. These results suggest that PPARγ ligands may be of therapeutic value in inflammatory diseases.
42. ••], it is shown that PPARγ agonists suppress monocyte elaboration of inflammatory cytokines.
43. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:1998;241-252. It is shown that the nuclear receptor PPARγ is induced in human monocytes following exposure to oxidized low-density lipoprotein. Furthermore, evidence is provided for high levels of PPARγ in the foam cells of atherosclerotic lesions. In myelomonocytic cell lines, ligand activation of the PPARγ-RXRα heterodimer induces a monocytic-like differentiation and uptake of oxidized low-density lipoprotein is increased through transcriptional induction of the scavenger receptor CD36. These results give insight into lipid metabolism in monocytic cells, and suggest that endogenous PPARγ is an important regulator of gene expression in these cells.
44. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPAR gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized LDL. Proc Natl Acad Sci USA. 95:1998;7614-7619.
45. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma. Cell. 93:1998;229-240. Macrophage uptake of oxidized low-density lipoprotein activates PPARγ-dependent transcription through a pathway involving the scavenger receptor CD36. Two oxidized lipid components of oxidized low-density lipoprotein, 9-HODE and 13-HODE, which are derived from linoleic acid, were identified as endogenous activators and ligands of PPARγ. These results suggest that PPARγ might be a key regulator of foam cell gene expression.
46. Law R.E., Meehan W.P., Xi X.P., Graf K., Wuthrich D.A., Coats W., Faxon D., Hsueh W.A. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 98:1996;1897-1905.
47. Fruchart J.C., Duriez P., Staels B. Peroxisome proliferator-activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherogenesis. Curr Opin Lipidol. 10:1999;245-257.
48. Bunte T., Hahman H.W., Hellwig N., Hau U., Becker D., Dyckmans J., Keller H.E., Schieffer H.J. Effect of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients. Atherosclerosis. 98:1993;127-138.
49. Ericsson C.G., Hamsten A., Nilsson J., Grip L., Svane B., De Fair U. Angiography assessment of effect of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:1996;849-853.
50. Frick M.H., Syvanne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., Kesaniemi Y.A., Pasternack A., Taskinen M.R. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels in HDL cholesterol. Lopid Coronary Trial (LOCAT) Study Group [see comments]. Circulation. 96:1997;2137-2143.
51. Kömüves L.G., Hanley K., Jiang Y., Elias P.M., Williams M.L., Feingold K.R. Ligands and activators of nuclear hormone receptors regulate epidermal differentiation during fetal rat skin development. J Invest Dermatol. 111:1998;429-433.
52. Hanley K., Jiang Y., He S.S., Friedman M., Elias P.M., Bikle D.D., Williams M.L., Feingold K.R. Keratinocytes differentiation is stimulated by activators of the nuclear hormone receptor PPAR alpha. J Invest Dermatol. 110:1998;368-375.
53. Lim H., Gupta R.A., Ma W., Paria B.C., Moller D.E., Morrow J.D., DuBois R.N., Trzaskos J.M., Dey S.K. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR delta. Genes Dev. 13:1999;1561-1574. Using cyclo-oxygenase-2 (COX2)-deficient mice, the authors demonstrate that COX2-derived prostacyclin is essential for embryo implantation. They provide evidence that the effects of prostacyclin are mediated by its activation of PPARδ, the expression of which is strongly induced at embryo implantation sites.
54. Keller H.J., Devchand P.R., Perroud M., Wahli W. PPARα structure-fuction relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem. 378:1997;651-655.